JANSSEN : 's Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
MarketScreener,
The Janssen Pharmaceutical Companies of Johnson
The Janssen Pharmaceutical Companies of Johnson
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a promising…
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Janssen's Updated Phase 1 Results for Teclistamab Suggest Deep, Durable Responses in Patients with Heavily Pretreated Multiple…
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a promising…
Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a promising…
Se han presentado los primeros resultados de la formulación subcutánea (SC) y se han actualizado los resultados de la formulación…
Präsentation erster Ergebnisse für die subkutan (SC) verabreichte Formulierung und aktualisierter Ergebnisse für die intravenös …
Présentation des premiers résultats pour la formulation sous-cutanée (SC) et des résultats actualisés pour la formulation…
Präsentation erster Ergebnisse für die subkutan (SC) verabreichte Formulierung und aktualisierter Ergebnisse für die intravenös …
Die Janssen Pharmaceutical Companies von Johnson
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
We continue to identify new treatment options, particularly for patients who have relapsed or become refractory to existing…
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
BEERSE, Belgium--(Business Wire)--The Janssen Pharmaceutical Companies of Johnson
First-reported results for the subcutaneous (SC) formulation and updated results for the intravenous (IV) formulation presented…
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with…
RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with…
First-reported results for the subcutaneous formulation and updated results for the intravenous formulation presented at ASH…
- The Janssen Pharmaceutical Companies of Johnson
New cilta-cel (BCMA CAR-T) data from the Phase 1b/2 CARTITUDE-1 study in relapsed or refractory multiple myeloma New DARZALEX® (d…
The development of the antibody followed Janssen Biotech, Inc.'s licensing agreement with Genmab for use of its…
- New cilta-cel (BCMA CAR-T) data from the Phase 1b/2 CARTITUDE-1 study in relapsed or refractory multiple myeloma- New DARZALEX®…
RARITAN, N.J., Nov. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., Nov. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
- New cilta-cel (BCMA CAR-T) data from the Phase 1b /2 CARTITUDE-1 study in relapsed or refractory multiple myeloma - New…
Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse…
- New cilta-cel (BCMA CAR-T) data from the Phase 1b/2 CARTITUDE-1 study in relapsed or refractory multiple myeloma - New…
Monitor and manage patients at risk for fractures according to established treatment guidelines and consider use of bone…
Presentations Distinguish Robust, Diverse Oncology Portfolio and Pipeline Across Hematologic Malignancies, Prostate Cancer and…
Presentations Distinguish Robust, Diverse Oncology Portfolio and Pipeline Across Hematologic Malignancies, Prostate Cancer and…
, /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
RARITAN, N.J., May 29, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Inc. Companies of Johnson
/ / -- The Janssen Pharmaceutical Companies of Johnson
Presentations Distinguish Robust, Diverse Oncology Portfolio and Pipeline Across Hematologic Malignancies, Prostate Cancer and…
/PRNewswire/ -- The of Johnson
/PRNewswire/ -- The of Johnson
Presentations Distinguish Robust, Diverse Oncology Portfolio and Pipeline Across Hematologic Malignancies, Prostate Cancer and…
Janssen Highlights Innovative Oncology Portfolio and Pipeline of Oral, Biologic and Cell Therapies Through ASCO20 Virtual…
Media Contacts: Brian Kenney Phone: +1 215-620-0111 Satu Glawe Phone: +49 172-294-6264 Investor Relations: Christopher…
Teclistamab Data Featured as an Oral Presentation during ASCO Virtual Scientific Program RARITAN, N.J.
Initial findings for teclistamab in this heavily pre-treated population support further study of this investigational dual-target…
Teclistamab Data Featured as an Oral Presentation during ASCO Virtual Scientific Program RARITAN, N.J.
Teclistamab Data Featured as an Oral Presentation during ASCO Virtual Scientific Program RARITAN, N.J.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
BEERSE, Belgium--(Business Wire)--The Janssen Pharmaceutical Companies of Johnson
Teclistamab Data Featured as an Oral Presentation during ASCO Virtual Scientific Program RARITAN, N.J.
Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed…
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson